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KEY  RESULT
STUDY DESIGN
OBJECTIVE
Question: What is the effect of dulaglutide (DU) 1.5 mg 
versus insulin glargine (Glar) in patients with type 2 
diabetes (T2D) that have different glycemic patterns?
■ The effects of DU 1.5 mg and Glar were compared in patients with T2D 
at 52 weeks from the AWARD-2 study with prevalent elevations in 
fasting glucose (FG), postprandial glucose (PPG), or both FG and PPG 
at baseline
■ Changes in glycated hemoglobin (A1c), FG, PPG, body weight, and 
hypoglycemia were investigated
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CONCLUSION
■ DU 1.5 mg resulted in a greater reduction in A1c compared with Glar at 52 weeks 
among patients with different glycemic patterns defined by FG and PPG levels at 
baseline
– Despite the limited sample size, statistically significant differences between 
treatments were found among the subgroups except for the low FG/high PPG 
subgroup
■ DU 1.5 mg resulted in a greater reduction in weight compared with Glar, whereas 
Glar increased weight among patients with different glycemic patterns
■ Results for documented symptomatic hypoglycemia were consistently lower for DU 
1.5 mg versus Glar in all subgroups
Limitations
■ This post hoc analysis had small sample sizes, especially for low FG/high PPG and 
high FG/low PPG subgroups
■ The median was chosen as the cutoff (i.e., not the clinical cut) due to sample size
– This may have influenced the results because the phenotype is less strictly 
defined
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Changes from Baseline for Fasting Plasma Glucose, Postprandial 
Glucose, and Body Weight at 52 Weeks
Documented Symptomatic Hypoglycemia for DU and GLAR and 
GLAR Dose in Subgroups 
Abbreviations: A1c, glycated hemoglobin; FG, fasting glucose; FPG, fasting plasma glucose; PPG, postprandial glucose; SD, standard 
deviation.
This is a post hoc analysis from the AWARD-2 study.1
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Schematic presentation depicting how patients 
were categorized into 4 groups based on combinations
of low and high FG and PPG, with median baseline
values of FG (151 mg/dL) and PPG (182 mg/dL) being
used as threshold for low and high, respectively. 
Cutoffs: Low FG (≤151); High FG (>151); 
Low PPG (≤182); High PPG (>182)
Baselinec
FPG (151 mg/dL) & 
PPG (182 mg/dL)
Group 1
Low FG, 
Low PPG;
n=183 
Group 2
Low FG, 
High PPG; 
n=57 
Group 3
High FG, 
Low PPG; 
n=63
Group 4
High FG, 
High PPG; 
n=201
a During the lead-in period, metformin (≥1500 mg) and glimepiride (≥4 mg) were titrated up to maximum tolerated dose, then doses were stable for 
6 to 8 weeks. Oral anti-hyperglycemic medications continued for the duration of the trial. b FG target: <100 mg/dL.43
c Median baseline values of FPG and PPG being used as threshold to define low and high values, respectively.
Abbreviations: DU, dulaglutide; FG, fasting glucose; FPG, fasting blood glucose; Glar, insulin glargine; PPG, postprandial glucose.
DU 1.5 mg resulted in a greater reduction of A1c when compared with Glar among patients with 
different glycemic patterns at 52 weeks
Glycemic patterns of glucose: A1c change from baseline at week 52 
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DU 1.5 mg
Glar
Baseline A1c, % 7.4 7.5 7.9 7.9 8.0 8.1 8.8 8.8
Least square mean for change in baseline at week 52.
*p˂.001 change from baseline; #p˂.05 for comparison with Glar; ##p˂.01 for comparison with Glar.
Abbreviations: A1c, glycated hemoglobin; DU, dulaglutide; FG, fasting glucose; Glar, insulin glargine; PPG, postprandial glucose.
Background
■ Glar exerts its action primarily through a decrease in hepatic glucose production and 
consequent lowering of FG with smaller effects on PPG and glucose excursions after 
meals
■ DU, a once-weekly GLP-1 receptor agonist (GLP-1RA), stimulates insulin secretion and 
suppresses glucagon levels both in the fasting and postprandial states, resulting in 
reductions of both FG and PPG
■ DU demonstrated greater reductions in A1c than Glar in AWARD-2 with better weight 
control and less hypoglycemia1
■ Patients with T2D are characterized by distinct glycemic patterns, with some of the 
patterns showing prevalent elevations in FG and/or PPG2
Variables
Low FG, 
Low PPG
n=292
Low FG, 
High PPG
n=90
High FG, 
Low PPG
n=92
High FG, 
High PPG
n=292
Overall
n=766
Age (years), 
mean (SD)
56.4 
(10.01)
56.3 
(8.76)
56.3 
(9.50)
56.8 
(9.29)
56.51 
(9.52) 
Male, n (%) 141 (48.3)
53
(58.9)
51
(55.4)
150
(51.4)
395 
(51.6) 
Duration of 
diabetes (years), 
mean (SD)
8.8
(6.29)
8.2
(5.23)
8.9
(6.69)
9.6
(5.83)
9.04 
(6.06)
A1c at baseline 
(%), mean (SD)
7.58 
(0.71)
7.93
(0.78)
7.98
(0.75)
8.78 
(0.97)
8.13 
(0.99) 
Weight, kg 84.87 (18.99)
83.16 
(19.19)
86.04 
(18.99)
88.70 
(17.60)
86.27 
(18.57)
Baseline FPG, 
mg/dL
126.30
(15.76)
134.09 
(11.81)
167.27 
(12.26)
195.11 
(35.43)
158.37 
(39.91)
Baseline PPG, 
mg/dL
150.54 
(20.47)
206.90 
(20.70)
163.48 
(14.03)
233.01 
(39.84)
190.15 
(47.49)
Low FG, 
Low PPG
Low FG, 
High PPG
High FG, 
Low PPG
High FG, 
High PPG
Variables DU 1.5 n=82
GLAR 
n=101
DU 1.5 
n=30 
GLAR 
n=27
DU 1.5 
n=35
GLAR 
n=28
DU 1.5 
n=108 
GLAR 
n=93
Documented symptomatic hypoglycemia at 52 weeks
n (%) 32 (39.0)
44 
(43.6)
12 
(40.0)
14
(51.9)
14 
(40.0)
12 
(42.9)
38 
(35.2)
47 
(50.5)
GLAR dose at 52 weeks, units
Mean (SD) -- 24.22 (20.35) --
30.15 
(39.15) --
24.57 
(11.96) --
33.05 
(19.90)
Abbreviations: DU, dulaglutide; FG, fasting glucose; GLAR, insulin glargine; PPG, postprandial glucose; SD, standard deviation.
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Glar resulted in a greater reduction of FPG when compared with DU, 
with the exception of the high FG/low PPG category. 
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Glucose values for FG and PPG are from self-monitored plasma glucose and central laboratory, respectively.
Least square mean for change from baseline at week 52. *p˂.05 and **p˂.001 change from baseline; ##p˂.01 for comparison with Glar. 
Abbreviations: DU, dulaglutide; FG, fasting glucose; FPG, fasting plasma glucose; Glar, insulin glargine; PPG, postprandial glucose.
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